Vertex Pharmaceuticals (VRTX) is back in focus after the U.S. Food and Drug Administration approved expanded use of CASGEVY for children as young as 2 with sickle cell disease or transfusion-dependent beta thalassemia.

Those CASGEVY headlines arrive during a strong run for Vertex Pharmaceuticals, with a 1-month share price return of 19.5% and year-to-date share price return of 16.8%, while the 5-year total shareholder return of 166.5% shows longer term momentum.

If this kind of gene therapy progress has your attention, it could be a good moment to widen your watchlist with a healthcare AI angle through the 40 healthcare AI stocks

With Vertex Pharmaceuticals now trading around $528 and sitting only about 4% below the average analyst price target, plus an estimated intrinsic value implying a larger discount, investors are left with a familiar question: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 3.6% Undervalued

On the latest narrative numbers, Vertex Pharmaceuticals is priced at $528.04 versus a fair value estimate of $547.72, with that fair value built on explicit revenue, margin and earnings assumptions that extend several years out.

Analysts are assuming Vertex Pharmaceuticals's revenue will grow by 10.0% annually over the next 3 years.

Analysts assume that profit margins will increase from 32.9% today to 37.0% in 3 years time.

Want to see what sits behind that revenue glide path and margin step up, and how those feed into a richer future earnings multiple and fair value outcome?

Result: Fair Value of $547.72 (UNDERVALUED)

However, the bullish Vertex Pharmaceuticals story still hinges on successful pipeline execution and resilient pricing. Setbacks in key trials or tighter reimbursement policies could quickly challenge that fair value narrative.

Next Steps

If this Vertex Pharmaceuticals narrative feels promising, treat it as a starting point rather than a conclusion and pressure test the data yourself. To see what has investors optimistic and how those positives stack up against the risks, review the 3 key rewards.

Looking for more investment ideas beyond Vertex Pharmaceuticals?

If Vertex Pharmaceuticals has sharpened your focus, do not stop here. Broaden your search now with fresh stock ideas screened around quality, value and resilience.

• Target resilient companies with steadier profiles by reviewing the 74 resilient stocks with low risk scores.
• Hunt for quality at attractive prices by checking the 44 high quality undervalued stocks.
• Spot stocks that combine solid financial footing with clean balance sheets through the solid balance sheet and fundamentals stocks screener (47 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.